Best of American Association for Cancer Research Annual Meeting | Conference

Cynthia X. Ma, MD, PhD, on Benefits of Attendance at AACR
May 30, 2021

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.

Cynthia X. Ma, MD, PhD, on Potential Immunotherapy Options for Patients With Metastatic Breast Cancer
May 22, 2021

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 about data supporting the potential use of the exemestane/leuprolide acetate plus pembrolizumab combination.

Andreana N. Holowatyj, PhD, MS, Talks AACR and the Value of the Annual Meeting 2021
May 12, 2021

Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.

Thomas Marron, MD, PhD, on the Value of Neoantigen Vaccines and Future Research
April 30, 2021

Marron spoke about the value that neoantigen vaccines can provide by studying T-cell responses and the characteristics of lymphoid response to antigens.

Matthew J. Matasar, MD, Discusses ‘Breadth of Scientific Investigation’ at AACR Annual Meeting
April 23, 2021

The lymphoma expert offered highlights from the meeting, with hopes that more treatment options will be available for patients with lymphoma.

Abdulraheem Yacoub, MD, on Advancing Outcomes for Patients With Myelofibrosis and Myeloproliferative Neoplasms
April 21, 2021

CancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.

Vivek Subbiah, MD, on Data from AACR on Resistance Mechanisms to KRAS Inhibitors
April 17, 2021

CancerNetwork® spoke with Vivek Subbiah, MD, during the virtual American Association for Cancer Research Annual Meeting 2021 to discuss the most important data to come out of the meeting regarding therapy for tumors harboring KRAS mutations.

Matthew D. Galsky, MD, on How Data in Neoadjuvant Therapy May Inform Future Research Across Tumor Types
April 16, 2021

CancerNetwork® spoke with Matthew D. Galsky, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss leading data to come out of the meeting and what it means for the future of cancer systemic therapy.